Polycystic Kidney Disease - Pipeline Review, H2 2015 Is Released Polycystic Kidney Disease - Pipeline Review, H2 2015 Summary Global Markets Direct s, Polycystic Kidney Disease - Pipeline Review, H2 2015, provides an overview of the Polycystic Kidney Disease s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Polycystic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Polycystic Kidney Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Polycystic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Polycystic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Polycystic Kidney Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Polycystic Kidney Disease pipeline depth and focus of Indication therapeutics 1
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179118/polycystic-kidney-disease-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Polycystic Kidney Disease Overview 9 Therapeutics Development 10 Pipeline Products for Polycystic Kidney Disease - Overview 10 Pipeline Products for Polycystic Kidney Disease - Comparative Analysis 11 Polycystic Kidney Disease - Therapeutics under Development by Companies 12 Polycystic Kidney Disease - Therapeutics under Investigation by Universities/Institutes 13 Polycystic Kidney Disease - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Polycystic Kidney Disease - Products under Development by Companies 17 Polycystic Kidney Disease - Products under Investigation by Universities/Institutes 18 Polycystic Kidney Disease - Companies Involved in Therapeutics Development 19 2
DiscoveryBiomed, Inc. 19 Endocyte, Inc. 20 IC-MedTech, Inc. 21 Ipsen S.A. 22 Kadmon Corporation, LLC 23 Metabolic Solutions Development Company, LLC 24 Otsuka Holdings Co., Ltd. 25 Synta Pharmaceuticals Corp. 26 Polycystic Kidney Disease - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Combination Products 28 Assessment by Target 29 Assessment by Mechanism of Action 31 Assessment by Route of Administration 33 Assessment by Molecule Type 35 Drug Profiles 37 (ascorbic acid + menadione) - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 CIM-2 - Drug Profile 39 Product Description 39 Mechanism of Action 39 3
R&D Progress 39 DBM-43H11 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Drugs for Polycystic Kidney Disease - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 EC-0371 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 GLG-302 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 JP-153 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 lanreotide acetate - Drug Profile 46 Product Description 46 Mechanism of Action 46 4
R&D Progress 46 MSDC-0160 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 MSDC-0602 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 oxypurinol - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 pyrimethamine - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecules to Activate AMPK for Polycystic Kidney Disease - Drug Profile 55 Product Description 55 5
Mechanism of Action 55 R&D Progress 55 Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules to Inhibit Hsp90 for Polycystic Kidney Disease - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Small Molecules to Target CIL-1 for Genetic Disorders and Polycystic Kidney Disease - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 STA-2842 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 tesevatinib tosylate - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 tolvaptan - Drug Profile 62 6
Product Description 62 Mechanism of Action 62 R&D Progress 62 Read More http://www.idatainsights.com/reports-landing-page.php?id=179118/polycystic-kidneydisease-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
7